Vericiguat Initiation and Titration
Start vericiguat at 2.5 mg once daily with food, then double the dose approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient. 1
Starting Dose and Administration
- Initial dose: 2.5 mg orally once daily with food 1
- Tablets may be crushed and mixed with water immediately before administration for patients unable to swallow whole tablets 1
- If a dose is missed, take it as soon as remembered on the same day—do not take two doses on the same day 1
Titration Schedule
The titration follows a straightforward doubling protocol:
- Start: 2.5 mg once daily
- After ~2 weeks: Increase to 5 mg once daily (if tolerated)
- After another ~2 weeks: Increase to 10 mg once daily (target dose) 1
The target maintenance dose of 10 mg once daily was achieved in approximately 56% of patients in real-world Italian practice 2, and nearly 90% of patients in the VICTORIA trial were adherent to the 10 mg dose 3. The mean daily dose achieved in clinical trials was 9.2 mg 4, 5.
Monitoring During Titration
Key parameters to monitor:
- Blood pressure: Hypotension occurred in 9.1% of vericiguat patients vs 7.9% on placebo in VICTORIA 6. In real-world Japanese practice, 25.3% experienced hypotension within 90 days (mostly asymptomatic at 17.9%), but drug discontinuation due to hypotension was infrequent at only 4.4% 7
- Hemoglobin: Anemia occurred in 10% of vericiguat patients vs 7% on placebo 1
- Renal function and electrolytes: Standard monitoring as with other HFrEF therapies
Risk Factors for Hypotension
Patients at higher risk for hypotension include those with:
- Systolic blood pressure <100 mmHg at baseline (41.8% of real-world patients) 7
- Low body mass index 7
- In-hospital vericiguat initiation 7
Despite the systolic BP ≥100 mmHg criterion in your clinical scenario, be aware that hypotension can still occur but rarely necessitates discontinuation.
Clinical Context from VICTORIA Trial
The pivotal VICTORIA trial enrolled patients with chronic HF (NYHA class II-IV), LVEF <45%, who had recent worsening HF (hospitalization or outpatient IV diuretics) 6. Over a median 10.8 months, vericiguat reduced the composite of cardiovascular death or HF hospitalization by 10% (HR 0.90,95% CI 0.82-0.98, P=0.02), with an absolute event-rate reduction of 4.2 events per 100 patient-years and number needed to treat of 24 3.
Practical Implementation Considerations
Vericiguat should be added on top of optimized guideline-directed medical therapy (ACE-I/ARB/ARNI, beta-blocker, MRA, SGLT2i) 4, 5. Real-world data shows vericiguat was initiated after the first worsening HF episode in 54% of cases and during hospitalization in 50% 2.
Tolerability is generally excellent: Only 3% treatment discontinuation in real-world Italian practice 2, and syncope occurred in just 4.0% vs 3.5% on placebo 6.
Special Populations
- No dose adjustment needed for renal or hepatic impairment (though severe hepatic impairment was excluded from your scenario)
- Elderly patients: The drug has been studied and appears safe in older populations, though frailty and multimorbidity require individualized monitoring 8
Contraindications and Precautions
- Absolute contraindications: Concomitant use of other sGC stimulators; pregnancy 1
- Pregnancy testing required before initiation in females of reproductive potential 1
- PDE-5 inhibitors: Concomitant use is not recommended 1
The evidence strongly supports this straightforward titration protocol, with the FDA label 1 providing the definitive dosing guidance, reinforced by contemporary guidelines 4, 5 and validated by real-world implementation studies 2, 7.